Mr Frédéric Amar appointed Executive Director and CEO
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that all proposed resolutions at today’s EGM were passed.
The Board of Director of Cryo-Save proposed to its shareholders to appoint Mr. Frédéric Amar as Executive Director for a period of 4 years until the annual general meeting of shareholders of 2018. After the adoption of this resolution by the extraordinary meeting of shareholders, the Board of Directors unanimously appointed Mr. Amar as Chief Executive Officer (CEO) of Cryo-Save.
Mr. Amar (1964, French nationality) obtained a degree in Crystallography (1990) and a degree in Pharmacy (Pharm.D.) from the Université de Pharmacie of Marseilles (1992). In 1995, Mr. Amar founded A Telecom S.A., a Marseilles based private telecom operator concentrated on business customers, which after reaching 1 million minutes voice traffic per day and a headcount of 400 employees was sold to Tiscali S.p.A. in March 2000. In November 2011, Mr. Amar founded Salveo Biotechnology S.A., a Geneva based private laboratory specialized in stem cells cryopreservation and cell culture and involved in cellular therapeutic applications research, with a presence in Italy, Spain, Switzerland and Ukraine.
Mr. Amar has a strong scientific background and track record in creating and managing companies as well as a deep knowledge about the technique of and markets for stem cells cryopreservation. The Board of Directors expects that Mr. Amar will accelerate the initiated turnaround of the company and create value for shareholders and other stakeholders.
The Board of Directors would like to thank Ms. Evi Mattil who served as the CEO a/i since June 2013.
+ 31 (0) 575 548 998
Walter van Pottelberge, Chairman